DAWN News and Press, Day One Biopharmaceuticals Inc. From 02/24/26

OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 tria...

BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases,...

2026-02-03 17:20:03 ET On Feb. 2, 2026, AIGH Capital Management LLC reported a complete sale of its Lumen Technologies (NYSE:LUMN) stake, with an estimated transaction value of $15.61 million based on quarterly average pricing. According to an SEC filing dated Feb. 2, 2026, ...

2026-01-13 00:35:59 ET Day One Biopharmaceuticals, Inc. (DAWN) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 8:15 PM EST... Read the full article on Seeking Alpha For further details see: Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. M...

2026-01-12 12:34:37 ET More on Day One Biopharmaceuticals Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish Day One Biopharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation Day One Biopharmaceuticals: Mersana Acquisition Ignit...

2026-01-12 08:59:15 ET Denver, Colorado- Markets are waking up to a familiar but powerful theme this morning: companies that spent years building quietly are now flipping the switch to scale. Across advanced materials, AI infrastructure, diagnostics, and biotech, today’s news flow hi...

Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate progress and priorities for 2026 during J.P. Morgan Healthcare Conference, January 12th at ...

BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the succ...

2025-12-18 15:46:43 ET Investment Overview - Company & Q3 Earnings Overview - Reasons To Be Bullish Back in April 2024, I assigned Day One Biopharmaceuticals, Inc. ( DAWN ) stock a "Hold" rating in a note for the Seeking Alpha, covering the news that its lead asset tovor...

BRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening dis...